Human leucocyte antigen class I-redirected anti-tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells

Clinical and Experimental Immunology

Volumn 187, Issue 1, 2017, Pages 124-137

  Tan, M P ^a   Dolton, G M ^a   Gerry, A B ^b   Brewer, J E ^b   Bennett, A D ^b   Pumphrey, N J ^b   Jakobsen, B K ^b   Sewell, A K ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b Adaptimmune Ltd   (United Kingdom)

Author keywords

CD4+ T cells; immunotherapy; MHC class I; TCR affinity

Indexed keywords

GRANZYME B; HLA ANTIGEN CLASS 1; LENTIVIRUS VECTOR; PERFORIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; CANCER VACCINE; CTAG1B PROTEIN, HUMAN; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; MELANOCYTE PROTEIN PMEL 17; MEMBRANE PROTEIN; PROTEIN BINDING;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DEGRANULATION ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MEASUREMENT; PRIORITY JOURNAL; RECEPTOR BINDING; T CELL CULTURE; TARGET CELL; TUMOR IMMUNOLOGY; ADOPTIVE IMMUNOTHERAPY; CELL LINE; COMPARATIVE STUDY; CYTOTOXICITY; GENE THERAPY; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASMS; PROCEDURES; TRANSGENE;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; GENETIC THERAPY; GP100 MELANOMA ANTIGEN; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MEMBRANE PROTEINS; NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; TRANSGENES;

EID: 85002678464     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12828     Document Type: Article

References (47)

1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342:1432–3.
2. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013; 13:525–41.
3. Schumacher TN. T cell-receptor gene therapy. Nat Rev Immunol 2002; 2:512–9.
4. Aleksic M, Liddy N, Molloy PE et al. Different affinity windows for virus and cancer-specific T cell receptors: implications for therapeutic strategies. Eur J Immunol 2012; 42:3174–9.
5. Cole DK, Pumphrey NJ, Boulter JM et al. Human TCR-binding affinity is governed by MHC class restriction. J Immunol 2007; 178:5727–34.
6. Robbins PF, Morgan RA, Feldman SA et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29:917–24.
7. Cameron BJ, Gerry AB, Dukes J et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med 2013; 5:197ra03.
8. Henry M. Adaptimmune announces interim results from pilot trial of its engineered NY-ESO T cells targeting synovial sarcoma. Adaptimmune press release, 17 October, 2014.
9. Tan MP, Gerry AB, Brewer JE et al. T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells. Clin Exp Immunol 2015; 180:255–70.
10. Irving M, Zoete V, Hebeisen M et al. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem 2012; 287:23068–78.
11. Schmid DA, Irving MB, Posevitz V et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 2010; 184:4936–46.
12. Bos R, Marquardt KL, Cheung J, Sherman LA. Functional differences between low- and high-affinity CD8(+) T cells in the tumor environment. Oncoimmunology 2012; 1:1239–47.
13. Udyavar A, Geiger TL. Rebalancing immune specificity and function in cancer by T cell receptor gene therapy. Arch Immunol Ther Exp (Warsz) 2010; 58:335–46.
14. Fujiwara H, Ochi T, Ochi F et al. Antileukemia multifunctionality of CD4 T cells genetically engineered by HLA class I-restricted and WT1-specific T cell receptor gene transfer. Leukemia 2015; 29:2393–401.
15. Odunsi K, Qian F, Matsuzaki J et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA 2007; 104:12837–42.
16. Matsuzaki J, Tsuji T, Luescher IF et al. Direct tumor recognition by a human CD4(+) T cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep 2015; 5:14896.
17. Ray S, Chhabra A, Chakraborty NG et al. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol 2010; 136:338–47.
18. Willemsen R, Ronteltap C, Heuveling M, Debets R, Bolhuis R. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha. Gene Ther 2005; 12:140–6.
19. Tsuji T, Yasukawa M, Matsuzaki J et al. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T cell receptor genes. Blood 2005; 106:470–6.
20. Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MI. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T cell receptor. Cancer Res 2005; 65:1570–6.
21. Chhabra A, Yang L, Wang P et al. CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol 2008; 181:1063–70.
22. Xue SA, Gao L, Ahmadi M et al. Human MHC Class I-restricted high avidity CD4 T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology 2013; 2:e22590.
23. Morris EC, Tsallios A, Bendle GM, Xue SA, Stauss HJ. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci USA 2005; 102:7934–9.
24. Purbhoo MA, Boulter JM, Price DA et al. The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. J Biol Chem 2001; 276:32786–92.
25. Cole DK, Laugel B, Clement M, Price DA, Wooldridge L, Sewell AK. The molecular determinants of CD8 co-receptor function. Immunology 2012; 137:139–48.
26. Wooldridge L, van den Berg HA, Glick M et al. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem 2005; 280:27491–501.
27. Wooldridge L, Laugel B, Ekeruche J et al. CD8 controls T cell cross-reactivity. J Immunol 2010; 185:4625–32.
28. Chervin AS, Stone JD, Soto CM et al. Design of T cell receptor libraries with diverse binding properties to examine adoptive T cell responses. Gene Ther 2013; 20:634–44.
29. Soto CM, Stone JD, Chervin AS et al. MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother 2012; 62:359–69.
30. Zhao Y, Bennett AD, Zheng Z et al. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol 2007; 179:5845–54.
31. Storkus WJ, Howell DN, Salter RD, Dawson JR, Cresswell P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol 1987; 138:1657–9.
32. Henderson RA, Michel H, Sakaguchi K et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 1992; 255:1264–6.
33. Miles KM, Miles JJ, Madura F, Sewell AK, Cole DK. Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability. Mol Immunol 2011; 48:728–32.
34. Robbins PF, Li YF, El-Gamil M et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 2008; 180:6116–31.
35. Lissina A, Ladell K, Skowera A et al. Protein kinase inhibitors substantially improve the physical detection of T cells with peptide-MHC tetramers. J Immunol Methods 2009; 340:11–24.
36. Wooldridge L, Lissina A, Vernazza J et al. Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region. Eur J Immunol 2007; 37:1323–33.
37. Holler PD, Kranz DM. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 2003; 18:255–64.
38. Laugel B, van den Berg HA, Gostick E et al. Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J Biol Chem 2007; 282:23799–810.
39. Price DA, Klenerman P, Booth BL, Phillips RE, Sewell AK. Cytotoxic T lymphocytes, chemokines and antiviral immunity. Immunol Today 1999; 20:212–6.
40. Price DA, Sewell AK, Dong T et al. Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Curr Biol 1998; 8:355–8.
41. Kuball J, Schmitz FW, Voss RH et al. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 2005; 22:117–29.
42. Rapoport AP, Stadtmauer EA, Binder-Scholl GK et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 2014; 21:914–21.
43. Johnson LA, Morgan RA, Dudley ME et al. Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114:535–46.
44. Johnson LA, Heemskerk B, Powell DJ Jr et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 2006; 177:6548–59.
45. Yang I, Kremen TJ, Giovannone AJ et al. Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg 2004; 100:310–9.
46. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75:163–89.
47. Purbhoo MA, Sutton DH, Brewer JE et al. Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J Immunol 2006; 176:7308–16.